Cohance Lifesciences Ltd · NSE:COHANCE
Cohance Lifesciences — Suven Pharmaceuticals — Q4 FY2020 Earnings Presentation
13 slides from Cohance Lifesciences's earnings presentation, Jun 18, 2020
Slide 1: SUVEN Pharmaceuticals Communication to Investors
SUVEN Pharmaceuticals Communication to Investors Mar 2020 18-Jun-20
Slide 2: Risk statement
Risk statement Except for historical information, all the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve number of risks and uncertainties. Although Suven Pharmaceuticals attempts to be a
Slide 3: Financial Snapshot
Financial Snapshot Financial Snapshot All figures are in INR Million, other than ratios and EPS Standalone - Quarterly Standalone - Annual (1) Consolidated - Annual (2) Q4 Mar 20 Q3 Dec 19 QoQ Growth Q4 Mar 19 QoQ Growth FY Mar 20 FY Mar 19 YoY Growth FY Mar 20 FY Mar 19 YoY Growth Revenue 1,901.05
Slide 4: Q4 to Q3 Comparison
Q4 to Q3 COMPARISON INR Million REVENUE PROFIT 2,100.00 1,835.94 1,901.05 600.00 532.41 519.99 1,600.00 500.00 400.00 1,100.00 300.00 600.00 200.00 100.00 100.00 Q3 Dec 19 Q4 Mar 20 Q3 Dec 19 Q4 Mar 20 EBIT EBIDTA 900.00 900.00 845.47 826.97 789.48 756.43 700.00 700.00 500.00 500.00 300.00 300.00 10
Slide 5: YoY Comparison
YoY COMPARISON(1) INR Million REVENUE PROFIT 9,000.00 8,519.07 3,000.00 2,700.80 8,000.00 2,500.00 7,000.00 6,000.00 2,000.00 5,000.00 3,784.35 1,500.00 4,000.00 1,092.74 3,000.00 2,513.34 1,000.00 748.23 1,901.05 532.41 2,000.00 500.00 1,000.00 - - Q4 Mar 19 Q4 Mar 20 FY Mar 19 FY Mar 20 Q4 Mar 19
Slide 6: Additional information
Additional information • Suven Pharmaceuticals (your Company) is focused on the business of Contract Development and Manufacturing Operations (CDMO). • During the year, Suven Life Sciences Limited, (Group company), a 30 years old entity, demerged CRAMS business undertaking, now integrated to your Co
Slide 7: Additional information
Additional information • On 30 Jan 2020, the World Health Organization (WHO) declared the coronavirus (COVID-19) outbreak a “Public Health Emergency of International Concern” and on 11 Mar 2020, declared it to be pandemic. Actions taken around the world to help mitigate the spread of the coronavirus
Slide 8: Background
Background 18-June-20 2019-20 Q4 results
Slide 9: Business Model – Post Demerger
Business Model – Post Demerger Process Pre-Clinical Regulatory / Specialty Innovation & Human Clinical Research / Formulation Formulation Commercial Chemicals / Patenting Development Studies Custom Development Commercial Launch API Synthesis Contract NCE Research Development and Manufacturing (Drug
Slide 10: Multi Location Facilities
Multi Location Facilities § 300 CM reactors (93) § 500L to 10 KL GL/SS Pashamylaram, § GMP Intermediates Telangana, India Suryapet, Telangana, Vizag, Andhra Banjara Hills, Hyderabad, SUVEN API & India Pradesh, India India Formulation Facility SUVEN Intermediate Corporate Office Mfg. Facility § 307 K
Slide 11: Business Fundamentals
Business Fundamentals • Strong research and execution capability • Shareholder value creation • Consistent Dividend payment • Prudent utilization of cash flows • Low debt • Customer value creation & long-term relationship 18-June-20
Slide 12: Business Drivers
Business Drivers • Repeat business owing to long standing relationships with MNC companies • Long term commercial supply opportunity with the launch of product by global sponsors • Working with innovator companies in developed markets having stringent regulations – reflection of our research skills
Slide 13: Contacts
Contacts Suven Pharmaceuticals Limited Serene Chambers, Road No. 5, Avenue 7, Banjara Hills, Hyderabad 500034 http://www.suvenpharm.com Contact us: +91 40 2354 1142/3314 info@suvenpharm.com 18-June-20
Suven Pharmaceuticals — Q4 FY2020 Earnings Presentation on 6ix